涂片阳性/Xpert阴性结果早期预测临床标本中存在非结核分枝杆菌的可靠性

doi:10.19982/j.issn.1000-6621.20240300

中国防痨杂志 ›› 2025, Vol. 47 ›› Issue (1): 61-65.doi: 10.19982/j.issn.1000-6621.20240300

涂片阳性/Xpert阴性结果早期预测临床标本中存在非结核分枝杆菌的可靠性

赵悦¹^,², 王昊然¹, 程美锦², 王伟², 梁瑞霞³, 黄海荣¹()

¹首都医科大学附属北京胸科医院国家结核病临床实验室,北京 101149
²河南省胸科医院医学检验科,郑州 450000
³河南省胸科医院结核内科,郑州 450000

收稿日期:2024-07-23 出版日期:2025-01-10 发布日期:2025-01-02
通信作者: 黄海荣 E-mail:nclhuang@ccmu.edu.cn
基金资助:
国家重点研发计划(2022YFC2305203);北京市卫生健康委员会高层次公共卫生人才(G2023-2-002)

The evaluation of the smear-positive and Xpert-negative outcome as an early indicator of nontuberculous mycobacteria existence in clinical specimen

Zhao Yue¹^,², Wang Haoran¹, Cheng Meijin², Wang Wei², Liang Ruixia³, Huang Hairong¹()

¹National Clinical Laboratory on Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China
²The Clinical Laboratory, Henan Provincial Chest Hospital, Zhengzhou 450000, China
³The Tuberculosis Department, Henan Provincial Chest Hospital, Zhengzhou 450000, China

Received:2024-07-23 Online:2025-01-10 Published:2025-01-02
Contact: Huang Hairong E-mail:nclhuang@ccmu.edu.cn
Supported by:
The National Key Research and Development Program of China(2022YFC2305203);Beijing Public Health Experts Project(G2023-2-002)

摘要/Abstract

摘要：

目的：评估涂片阳性/Xpert阴性结果用于早期预测临床标本中存在非结核分枝杆菌(non-tuberculous mycobacteria,NTM)的可靠性。方法：回顾性分析河南省胸科医院2019年1月至2024年4月新发肺部疾病就诊且涂片显微镜检查报告阳性结果的患者和分离培养鉴定出NTM的患者的实验室检查资料。分析涂片阳性/Xpert阴性结果作为患者分离鉴定出NTM预测指标的准确性。对研究期间培养鉴定为NTM的患者,分析其获得涂片阳性/Xpert阴性结果的比例,了解此预测指标的敏感度;分析涂片阳性的结核病患者中出现Xpert检测阴性结果的比例,了解预测指标的特异度。结果：在纳入的涂片阳性患者中,8.22%(202/2458)的患者同期开展的Xpert检测结果为阴性。在148例涂片阳性/Xpert阴性结果且具有同期培养鉴定结果的患者中,138例(93.24%)培养鉴定出NTM,表明涂片阳性/Xpert阴性结果早期预测临床标本中存在NTM具有良好的准确性。增加γ-干扰素释放试验阴性结果的附加条件后,预测的准确性达到100.00%(73/73),但预测敏感度大幅降低(37.61%,44/117)。在分离鉴定为NTM病的患者中,涂片阳性/Xpert阴性结果预测NTM存在的敏感度为39.78%(109/274),而在涂阳结核病患者中,该指标的特异度为99.56%(2256/2266)。结论：在疑似结核病患者中,涂片阳性/Xpert阴性结果是一项早期、可靠的NTM分离预测指标。

关键词: 非典型性细菌, 分枝杆菌属, 诊断,鉴别, 预测

Abstract:

Objective: To evaluate the diagnostic reliability of smear-positive/Xpert-negative results as an early predictor for the presence of non-tuberculous mycobacteria (NTM) in clinical specimens. Methods: A retrospective analysis was conducted on laboratory examination data from patients newly diagnosed with pulmonary diseases at Henan Chest Hospital between January 2019 and April 2024. The dataset included cases with positive smear microscopy results and those with NTM confirmed by isolation and culture. The accuracy of smear-positive/Xpert-negative results as a predictive indicator for NTM isolation and identification was assessed. The proportion of patients diagnosed with NTM during the study period who presented smear-positive/Xpert-negative results was analyzed to evaluate the sensitivity of this predictive indicator. Additionally, the proportion of smear-positive tuberculosis patients with negative Xpert test results was examined to determine the specificity of this indicator. Results: Among the smear-positive patients included in the study, 8.22% (202/2458) exhibited negative Xpert test results during the same period. Of the 148 patients with smear-positive/Xpert-negative results and concurrent culture-based identification, 138 cases (93.24%) were confirmed as NTM through culture, demonstrating the high accuracy of smear-positive/Xpert-negative results as an early predictor for NTM in clinical specimens. When the additional criterion of a negative interferon-gamma release assay (IGRA) result was applied, the predictive accuracy increased to 100.00% (73/73). However, this refinement significantly reduced the sensitivity of the prediction to 37.61% (44/117). The sensitivity of smear-positive/Xpert-negative results in predicting the presence of NTM was 39.78% (109/274) among patients with NTM disease. Conversely, the specificity of this indicator was remarkably high at 99.56% (2256/2266) among patients with smear-positive tuberculosis. Conclusion: In patients suspected of tuberculosis, smear-positive/Xpert-negative results serve as an early and reliable predictor for the identification of NTM.

Key words: Atypical bacterial forms, Mycobacterium, Diagnosis, differential, Forecasting

中图分类号:

R378.91
R563

赵悦, 王昊然, 程美锦, 王伟, 梁瑞霞, 黄海荣. 涂片阳性/Xpert阴性结果早期预测临床标本中存在非结核分枝杆菌的可靠性[J]. 中国防痨杂志, 2025, 47(1): 61-65. doi: 10.19982/j.issn.1000-6621.20240300

Zhao Yue, Wang Haoran, Cheng Meijin, Wang Wei, Liang Ruixia, Huang Hairong. The evaluation of the smear-positive and Xpert-negative outcome as an early indicator of nontuberculous mycobacteria existence in clinical specimen[J]. Chinese Journal of Antituberculosis, 2025, 47(1): 61-65. doi: 10.19982/j.issn.1000-6621.20240300

参考文献 20

[1]	Johansen MD, Herrmann JL, Kremer L. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat Rev Microbiol, 2020, 18(7): 392-407. doi:10.1038/s41579-020-0331-1. URL pmid: 32086501
[2]	Adjemian J, Olivier KN, Seitz AE, et al. Prevalence of nontuberculous mycobacterial lung disease in US Medicare beneficiaries. Am J Resp Crit Care, 2012, 185(8): 881-886. doi:10.1164/rccm.201111-2016OC. URL pmid: 22312016
[3]	van der Werf MJ, Ködmön C, Katalinic'-Jankovic' V, et al. Inventory study of non-tuberculous mycobacteria in the European Union. BMC Infect Dis, 2014, 14:62. doi:10.1186/1471-2334-14-62. URL pmid: 24502462
[4]	Baldwin SL, Larsen SE, Ordway D, et al. The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases. PLoS Negl Trop Dis, 2019, 13(2):e0007083. doi:10.1371/journal.pntd.0007083.
[5]	Wang X, Li H, Jiang G, et al. Prevalence and drug resistance of nontuberculous mycobacteria, northern China, 2008—2011. Emerg Infect Dis, 2014, 20(7): 1252-1253. doi:10.3201/eid2007.131801.
[6]	Seki M, Kim CK, Hayakawa S, et al. Recent advances in tuberculosis diagnostics in resource-limited settings. Eur J Clin Microbiol Infect Dis, 2018, 37(8):1405-1410. doi:10.1007/s10096-018-3258-y.
[7]	Shahraki AH, Heidarieh P, Bostanabad SZ, et al. “Multidrug-resistant tuberculosis” may be nontuberculous mycobacteria. Eur J Intern Med, 2015, 26(4): 279-284. doi:10.1016/j.ejim.2015.03.001.
[8]	Liang Q, Jiang X, Jia J, et al. An early and trustable indicator suggestive of non-tuberculosis mycobacteria isolation in a high tuberculosis burden setting. J Infect, 2024, 88(5):106149. doi:10.1016/j.jinf.2024.106149.
[9]	Steingart KR, Sohn H, Schiller I, et al. Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev, 2014(1): CD009593. doi:10.1002/14651858.CD009593.pub2.
[10]	Leyten EM, Prins C, Bossink AW, et al. Effect of tuberculin skin testing on a Mycobacterium tuberculosis-specific interferon-gamma assay. Eur Respir J, 2007, 29(6):1212-1216. doi:10.1183/09031936.00117506. URL pmid: 17215314
[11]	Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol, 2008, 26(10):1135-1145. doi:10.1038/nbt1486. URL pmid: 18846087
[12]	Xu Y, Liang B, Du C, et al. Rapid Identification of Clinically Relevant Mycobacterium Species by Multicolor Melting Curve Analysis. J Clin Microbiol, 2019, 57(1):e01096-18. doi:10.1128/JCM.01096-18.
[13]	Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med, 2007, 175(4): 367-416. doi:10.1164/rccm.200604-571ST.
[14]	Yu X, Liu P, Liu G, et al. The Prevalence of non-tuberculosis mycobacterial infections in mainland China: Systematic review and meta-analysis. J Infect, 2016, 73(6):558-567. doi:10.1016/j.jinf.2016.08.020.
[15]	Simons S, van Ingen J, Hsueh PR, et al. Nontuberculous mycobacteria in respiratory tract infections, eastern Asia. Emerg Infect Dis, 2011, 17(3): 343-349. doi:10.3201/eid1703.100604. URL pmid: 21392422
[16]	Duan H, Han X, Wang Q, et al. Clinical Significance of Nontuberculous Mycobacteria Isolated From Respiratory Specimens in a Chinese Tuberculosis Tertiary Care Center. Sci Rep, 2016, 6:36299. doi:10.1038/srep36299. URL pmid: 27808247
[17]	Dorman SE, Schumacher SG, Alland D, et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis, 2018, 18(1):76-84. doi:10.1016/S1473-3099(17)30691-6. URL pmid: 29198911
[18]	Zhang Z, Du J, Liu T, et al. EasyNAT MTC assay: A simple, rapid, and low-cost cross-priming amplification method for detection of Mycobacterium tuberculosis suitable for point-of-care testing. Emerg Microbes Infect, 2021, 10(1): 1530-1535. doi:10.1080/22221751.2021.1959271.
[19]	Gao L, Lu W, Bai L, et al. Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis, 2015, 15(3): 310-319. doi:10.1016/S1473-3099(14)71085-0. URL pmid: 25681063
[20]	Broekmans JF, Migliori GB, Rieder HL, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J, 2002, 19(4):765-775. doi:10.1183/09031936.02.00261402. URL pmid: 11999007

涂片阳性/Xpert阴性结果早期预测临床标本中存在非结核分枝杆菌的可靠性

The evaluation of the smear-positive and Xpert-negative outcome as an early indicator of nontuberculous mycobacteria existence in clinical specimen

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 20

相关文章 15

编辑推荐

Metrics

本文评价

友情链接

[1]	刘菊秀, 张建华, 温均筠, 姜晓双. 吉林市结核分枝杆菌耐药情况及趋势预测分析[J]. 中国防痨杂志, 2025, 47(3): 348-354.
[2]	李琦, 王宇津, 王雪钰, 初乃惠, 聂文娟. 新型化合物舒达吡啶与克拉霉素药物代谢相互作用机制研究[J]. 中国防痨杂志, 2025, 47(2): 142-149.
[3]	柳晓蕾, 王海慧, 张汝姣, 崔蓉, 王凯, 田高清. 非结核分枝杆菌肺病并发肺曲霉菌病一例[J]. 中国防痨杂志, 2025, 47(1): 116-120.
[4]	范俊, 王恒, 兰汀隆, 董伟杰, 唐恺, 李元, 严广璇, 徐尚胜, 康志刚, 秦世炳. 12例非结核分枝杆菌性脊柱炎手术治疗患者临床特征及治疗转归[J]. 中国防痨杂志, 2025, 47(1): 87-95.
[5]	李欣欣. 脑梗死肺部感染患者营养状态管理及营养不良风险预测模型的构建和应用[J]. 中国防痨杂志, 2024, 46(S2): 265-267.
[6]	祝甜, 肖珍, 何秀, 朱菊花, 姚梦玲. 基于Khorana评分构建老年肺癌患者静脉血栓栓塞症风险预测模型[J]. 中国防痨杂志, 2024, 46(S1): 103-105.
[7]	王飞, 华朵, 郭建建, 刘畅, 韩璐, 任易. 2021—2023年武汉地区非结核分枝杆菌肺病患者特征分析[J]. 中国防痨杂志, 2024, 46(9): 1069-1076.
[8]	段鸿飞. 非结核分枝杆菌病诊治六十年[J]. 中国防痨杂志, 2024, 46(8): 863-868.
[9]	刘玲, 曾谊, 王进, 刘晓玲, 刘艳, 林霏申, 郭晶. 肺结核合并糖尿病患者营养不良预测模型的构建与验证[J]. 中国防痨杂志, 2024, 46(8): 903-909.
[10]	耿俊玲, 张伊楠, 潘洪秋. 结核病患者发生药物性肝损伤风险预测模型的构建与验证[J]. 中国防痨杂志, 2024, 46(6): 699-706.
[11]	滕冲, 王玉兰, 刘柳, 张芳, 黄飞, 李涛, 赵冰, 赵雁林, 欧喜超. 2013—2022年北京市东城区肺结核报告发病流行特征及发病预测分析[J]. 中国防痨杂志, 2024, 46(4): 397-402.
[12]	程梦丽, 姜广路, 霍凤敏, 薛毅, 于霞. 夫西地酸对分枝杆菌的体外抑菌效果评价[J]. 中国防痨杂志, 2024, 46(4): 461-466.
[13]	杜姗姗, 沙巍, 王丽. 非结核分枝杆菌与其他呼吸道病原微生物合并感染的研究进展[J]. 中国防痨杂志, 2024, 46(12): 1535-1540.
[14]	陈振华, 郭婧玮, 王珏, 胡培磊, 易松林, 刘怡, 谭云洪. 基于BACTEC MGIT 960培养的结核分枝杆菌与非结核分枝杆菌混合感染检测方法的研究[J]. 中国防痨杂志, 2024, 46(10): 1243-1249.
[15]	孔含含, 张娇红, 曾剑锋, 操静. 老年肺结核患者衰弱风险预测模型的构建及验证[J]. 中国防痨杂志, 2024, 46(1): 85-91.